Clinical Trials Logo

Clinical Trial Summary

The main aim of this study is to learn about metachromatic leukodystrophy (MLD) in children and teenagers in Spain. This includes checking the number of new MLD cases and the frequency of children with MLD in 2022 in Spain. There is no treatment involved in this study. Participants' data will be taken from their medical records (charts), which were already collected as a part of their routine care between 01 January 2000 and 31 December 2022.


Clinical Trial Description

This is a non-interventional, retrospective study of participants diagnosed with late infantile or juvenile MLD whose data will be retrieved from existing health records. Data from all participants, diagnosed with MLD from 01 January 2000 to 31 December 2022 will be collected from health records, including demographic and clinical data from the pre-diagnosis until the date of data collection or death, whatever occurs first. The study will be conducted in Spain. The overall duration for data extraction is up to approximately 23 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05755568
Study type Observational
Source Takeda
Contact
Status Withdrawn
Phase
Start date November 30, 2023
Completion date July 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03725670 - Lentiviral Gene Therapy for MLD N/A
Terminated NCT01963650 - Natural History Study of Children With Metachromatic Leukodystrophy
Active, not recruiting NCT01887938 - An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy Phase 1/Phase 2
Active, not recruiting NCT03771898 - A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy Phase 2
Completed NCT00418561 - Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) Phase 1
Completed NCT01510028 - Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) Phase 1/Phase 2
Completed NCT01043640 - Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Phase 2
Terminated NCT01372228 - Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Phase 1/Phase 2